Taking It To The Front Lines: PD-1 Inhibitors Moving Earlier In Lung Cancer

With data on Merck’s pembrolizumab and Bristol’s nivolumab in lung cancer, the question has become whether the response rates are good enough to consider first-line therapy. It is also becoming a proving ground for PD-L1 expression as a biomarker for the class.